Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
Fate Therapeutics showcased clinical and preclinical data at the ASGCT Annual Meeting demonstrating the efficacy of its off-the-shelf CAR T-cell therapies FT819, FT839, and FT836. FT819 showed clinical activity in systemic lupus erythematosus (SLE) patients without the need for conditioning chemotherapy, achieving durable B cell depletion and lupus…